Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 667M | 654.9% |
| Gross Profit | 653M | 1163.6% |
| Cost of Revenue | 14M | 61.5% |
| Operating expense | 137M | 25% |
| Net Income | 519M | 740.1% |
| EBITDA | 516M | 1064% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 1.29B | 17.1% |
| Total Liabilities | 1.37B | 37.3% |
| Shares Outstanding | 178M | 10.8% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -186M | 7.1% |
| Cash from financing | -7.1M | 106.3% |
EPS
Financial Highlights for Novavax in Q1 '25
Novavax reported a revenue of 667M, which is a 654.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 653M, marking a 1163.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 14M, a -61.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 137M, showing a -25% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 519M, showing a 740.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 516M, showing a 1064% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Novavax with growth in revenue, gross profit, and net income.
